Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adiponectin | 3 | 2017 | 52 | 0.950 |
Why?
|
| Peptide Library | 4 | 2014 | 25 | 0.790 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 391 | 0.720 |
Why?
|
| Bacteriophages | 5 | 2013 | 43 | 0.700 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 1426 | 0.650 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 133 | 0.640 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 13 | 0.640 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2017 | 3 | 0.620 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2017 | 5 | 0.620 |
Why?
|
| Liposomes | 4 | 2011 | 107 | 0.570 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 286 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 2 | 2014 | 106 | 0.540 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 182 | 0.530 |
Why?
|
| Nanomedicine | 2 | 2014 | 32 | 0.520 |
Why?
|
| Viral Fusion Proteins | 2 | 2011 | 4 | 0.490 |
Why?
|
| Adipocytes | 2 | 2017 | 54 | 0.420 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 756 | 0.420 |
Why?
|
| Viral Proteins | 1 | 2013 | 172 | 0.410 |
Why?
|
| Nanoparticles | 2 | 2013 | 294 | 0.400 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 43 | 0.380 |
Why?
|
| Oligopeptides | 1 | 2010 | 97 | 0.370 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2006 | 6 | 0.290 |
Why?
|
| Endothelin-1 | 1 | 2006 | 54 | 0.280 |
Why?
|
| Cell Line, Tumor | 7 | 2014 | 2128 | 0.270 |
Why?
|
| Actins | 1 | 2006 | 142 | 0.270 |
Why?
|
| Doxorubicin | 3 | 2014 | 80 | 0.230 |
Why?
|
| 3T3-L1 Cells | 2 | 2017 | 14 | 0.230 |
Why?
|
| Protein Transport | 3 | 2014 | 286 | 0.230 |
Why?
|
| Capsid Proteins | 3 | 2012 | 60 | 0.210 |
Why?
|
| Dog Diseases | 1 | 2021 | 26 | 0.210 |
Why?
|
| Drug Carriers | 2 | 2011 | 121 | 0.180 |
Why?
|
| Female | 11 | 2022 | 19873 | 0.160 |
Why?
|
| Amino Acid Sequence | 4 | 2014 | 1124 | 0.160 |
Why?
|
| Thiazolidines | 1 | 2017 | 4 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 114 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2022 | 386 | 0.160 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 1490 | 0.150 |
Why?
|
| Signal Transduction | 1 | 2006 | 1802 | 0.150 |
Why?
|
| Neoplasms | 2 | 2021 | 1033 | 0.150 |
Why?
|
| Biological Transport | 1 | 2017 | 175 | 0.150 |
Why?
|
| Humans | 13 | 2022 | 34853 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 211 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 781 | 0.150 |
Why?
|
| Hep G2 Cells | 2 | 2013 | 52 | 0.140 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 376 | 0.140 |
Why?
|
| Blotting, Western | 3 | 2013 | 834 | 0.130 |
Why?
|
| Mice | 4 | 2017 | 5668 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 984 | 0.120 |
Why?
|
| Dogs | 2 | 2021 | 138 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 80 | 0.120 |
Why?
|
| Substrate Specificity | 1 | 2014 | 186 | 0.120 |
Why?
|
| Particle Size | 2 | 2011 | 200 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2017 | 1442 | 0.120 |
Why?
|
| Microscopy, Atomic Force | 1 | 2013 | 59 | 0.110 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 145 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2013 | 154 | 0.110 |
Why?
|
| Animals | 6 | 2021 | 14307 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 209 | 0.110 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1149 | 0.110 |
Why?
|
| Peptides | 2 | 2012 | 308 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 240 | 0.110 |
Why?
|
| Body Composition | 1 | 2012 | 146 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 445 | 0.100 |
Why?
|
| Immunomagnetic Separation | 1 | 2010 | 5 | 0.100 |
Why?
|
| Magnetics | 1 | 2010 | 36 | 0.100 |
Why?
|
| Static Electricity | 1 | 2010 | 75 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2010 | 123 | 0.100 |
Why?
|
| Biological Assay | 1 | 2010 | 56 | 0.100 |
Why?
|
| Apoptosis | 1 | 2017 | 1317 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2010 | 143 | 0.090 |
Why?
|
| Biosensing Techniques | 1 | 2010 | 81 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2010 | 226 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2012 | 775 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 550 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 522 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2003 | 115 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2010 | 653 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2006 | 420 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 63 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2003 | 4 | 0.060 |
Why?
|
| Mammaplasty | 1 | 2003 | 10 | 0.060 |
Why?
|
| Mastectomy | 1 | 2003 | 19 | 0.060 |
Why?
|
| Biology | 1 | 2022 | 15 | 0.060 |
Why?
|
| Cell Line | 1 | 2006 | 1289 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 794 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 302 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1152 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2012 | 1353 | 0.030 |
Why?
|
| Cachexia | 1 | 2012 | 7 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 2333 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2012 | 40 | 0.030 |
Why?
|
| Anthropometry | 1 | 2012 | 91 | 0.030 |
Why?
|
| Antibodies | 1 | 2012 | 135 | 0.030 |
Why?
|
| Weight Loss | 1 | 2012 | 124 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2012 | 322 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 242 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 60 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 154 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2012 | 167 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2010 | 17 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 42 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 96 | 0.020 |
Why?
|
| Drug Stability | 1 | 2011 | 110 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2011 | 70 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 186 | 0.020 |
Why?
|
| Freeze Fracturing | 1 | 2010 | 1 | 0.020 |
Why?
|
| Surface Properties | 1 | 2011 | 121 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 127 | 0.020 |
Why?
|
| Rhodamines | 1 | 2010 | 20 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 257 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 196 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 628 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 707 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 222 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 841 | 0.020 |
Why?
|
| Middle Aged | 3 | 2012 | 9642 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 11034 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 66 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2007 | 13 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 6448 | 0.020 |
Why?
|
| Male | 3 | 2012 | 18870 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 257 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 605 | 0.020 |
Why?
|
| Axilla | 1 | 2003 | 8 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2003 | 25 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 60 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 555 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 1961 | 0.010 |
Why?
|